Menu
Back to Journals » Clinical Ophthalmology » Volume 13
Ab interno canaloplasty combined with trabecular bypass stenting in eyes with primary open-angle glaucoma
Authors Heersink M, Dovich JA
Received 14 May 2019
Accepted for publication 9 July 2019
Published 12 August 2019 Volume 2019:13 Pages 1533—1542
DOI https://doi.org/10.2147/OPTH.S215667
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Marius Heersink,1 Jesse A Dovich2
1University of Alabama School of Medicine, Birmingham, AL, USA; 2Pacific Eye Institute, Upland, CA, USA
Purpose: Evaluate outcomes of trabecular meshwork (TM) bypass (iStent® GTS100) with cataract extraction (CE) and TM-bypass + ab interno canaloplasty (CP) (VISCO360®) with CE in patients with primary open-angle glaucoma (POAG).
Setting: Private surgical center for a comprehensive ophthalmology practice
Design: Retrospective analysis of 186 eyes from 130 consecutive patients with 6 months follow-up.
Methods: Eligible eyes had POAG, indicated for CE, and had received CE + TM-bypass or CE + TM-bypass + CP. Exclusions: glaucomas not POAG, SLT within 6 months, or previous ALT. IOP, visual acuity, and medication use assessed at baseline, months 1, 3, and 6. Endpoints were mean reduction in IOP from baseline at 6 months, proportion with IOP reduction at 6 months of ≥20% and IOP <18 mmHg on same or fewer medications, mean medication reduction, and proportion medication independent.
Results: Eighty-six eyes comprised the CE + TM-bypass + CP group; 100 eyes in the CE + TM-bypass group. At 6 months: mean IOP reduction was 2.9±3.6 mmHg for CE + TM-bypass + CP and 1.7±3.1 mmHg for CE + TM-bypass group (P<0.05); the proportion with IOP reduction of ≥20% and an IOP <18 mmHg on the same or fewer medications was 46% for CE + TM-bypass + CP and 35% for CE + TM-bypass; for both CE + TM-bypass + CP and CE + TM-bypass, mean number of medications was decreased (0.9 and 0.7, P<0.0001) with 56% and 48% off all medication. The most common AE were inflammation (6%) for CE + TM-bypass + CP group and VA loss (8%) for CE + TM-bypass.
Conclusion: At six months, a greater proportion of CE + TM-bypass + CP patients achieved IOP reduction of ≥20% and an IOP <18 mmHg on the same or fewer medications than for TM-bypass + CE.
Keywords: 360-degree viscodilation, canaloplasty, MIGS, glaucoma, VISCO360,® viscodilation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.